325 related articles for article (PubMed ID: 1834045)
21. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
Palatsi R; Reinilä M; Kivinén S
Acta Derm Venereol; 1986; 66(3):225-30. PubMed ID: 2426899
[TBL] [Abstract][Full Text] [Related]
22. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
Frölich M; Lachinsky N; Moolenaar AJ
Acta Endocrinol (Copenh); 1977 Feb; 84(2):333-42. PubMed ID: 138326
[TBL] [Abstract][Full Text] [Related]
23. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Balint-Perić L; Puzigaća Z
Gynecol Endocrinol; 1989 Dec; 3(4):269-80. PubMed ID: 2516704
[TBL] [Abstract][Full Text] [Related]
24. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
25. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study.
Carlborg L
Acta Obstet Gynecol Scand Suppl; 1986; 134():29-32. PubMed ID: 2949481
[TBL] [Abstract][Full Text] [Related]
26. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of oral contraceptives on acne. Apropos of a comparative study of Varnoline vs Diane in 69 women with acne].
Levrier M; Degrelle H; Bestaux Y; Bourry-Moreno M; Brun JP; Sailly F
Rev Fr Gynecol Obstet; 1988; 83(7-9):573-6. PubMed ID: 2973646
[TBL] [Abstract][Full Text] [Related]
28. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
29. [Management of virilization with an antiandrogen-containing contraceptive].
Apró G; Sas M
Orv Hetil; 1981 Jul; 122(30):1821-4. PubMed ID: 6458007
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial.
Schilling LH; Bolding OT; Chenault CB; Chong AP; Fleury F; Forrest K; Glick HI; Hasson HM; Heil CG; London RS
Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1264-8. PubMed ID: 2655451
[TBL] [Abstract][Full Text] [Related]
31. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
[TBL] [Abstract][Full Text] [Related]
32. [A new ovulation inhibitor antiandrogen].
Millet-part A; Blanes-espi A; Ferrer-barriendos J; Siqueira L; Acosta E
J Bras Ginecol; 1984 Mar; 94(3):91-7. PubMed ID: 12266391
[TBL] [Abstract][Full Text] [Related]
33. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
Akerlund M; Almström E; Högstedt S; Nabrink M
Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
[TBL] [Abstract][Full Text] [Related]
34. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives.
Aden U; Jung-Hoffmann C; Kuhl H
Contraception; 1998 Aug; 58(2):75-81. PubMed ID: 9773261
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a new triphasic oral contraceptive in private practice.
Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
[TBL] [Abstract][Full Text] [Related]
36. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
37. Oral contraceptives in the treatment of acne.
Tan JK; Degreef H
Skin Therapy Lett; 2001 Feb; 6(5):1-3. PubMed ID: 11242137
[TBL] [Abstract][Full Text] [Related]
38. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
Anderson FD
Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
[TBL] [Abstract][Full Text] [Related]
39. Three triphasic oral contraceptives now available in U.S.
Contracept Technol Update; 1985 Jan; 6(1):1-2, 4. PubMed ID: 12279912
[TBL] [Abstract][Full Text] [Related]
40. [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)].
Spona J; Huber J; Schmidt JB
Geburtshilfe Frauenheilkd; 1986 Jul; 46(7):435-8. PubMed ID: 3093307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
